Literature DB >> 21239717

Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells.

Wei Jiang1, Michael M Lederman, Clifford V Harding, Scott F Sieg.   

Abstract

Naive B lymphocytes are generally thought to be poor APCs, and there is limited knowledge of their role in activation of CD8(+) T cells. In this article, we demonstrate that class I MHC Ag presentation by human naive B cells is enhanced by TLR9 agonists. Purified naive B cells were cultured with or without a TLR9 agonist (CpG oligodeoxynucleotide [ODN] 2006) for 2 d and then assessed for phenotype, endocytic activity, and their ability to induce CD8(+) T cell responses to soluble Ags. CpG ODN enhanced expression of class I MHC and the costimulatory molecule CD86 and increased endocytic activity as determined by uptake of dextran beads. Pretreatment of naive B cells with CpG ODN also enabled presentation of tetanus toxoid to CD8(+) T cells, resulting in CD8(+) T cell cytokine production and granzyme B secretion and proliferation. Likewise, CpG-activated naive B cells showed enhanced ability to cross-present CMV Ag to autologous CD8(+) T cells, resulting in proliferation of CMV-specific CD8(+) T cells. Although resting naive B cells are poor APCs, they can be activated by TLR9 agonists to serve as potent APCs for class I MHC-restricted T cell responses. This novel activity of naive B cells could be exploited for vaccine design.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21239717      PMCID: PMC3039025          DOI: 10.4049/jimmunol.1001869

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells.

Authors:  A Krug; S Rothenfusser; V Hornung; B Jahrsdörfer; S Blackwell; Z K Ballas; S Endres; A M Krieg; G Hartmann
Journal:  Eur J Immunol       Date:  2001-07       Impact factor: 5.532

2.  Maintenance of serological memory by polyclonal activation of human memory B cells.

Authors:  Nadia L Bernasconi; Elisabetta Traggiai; Antonio Lanzavecchia
Journal:  Science       Date:  2002-12-13       Impact factor: 47.728

Review 3.  Granzymes (lymphocyte serine proteases): characterization with natural and synthetic substrates and inhibitors.

Authors:  C M Kam; D Hudig; J C Powers
Journal:  Biochim Biophys Acta       Date:  2000-03-07

4.  Morphological interactions of interdigitating dendritic cells with B and T cells in human mesenteric lymph nodes.

Authors:  K Takahashi; A Kenji; T Norihiro; K Eisaku; O Takashi; H Kazuhiko; Y Tadashi; A Tadaatsu
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

5.  Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation.

Authors:  Juliette Mouriès; Gabriel Moron; Géraldine Schlecht; Nicolas Escriou; Gilles Dadaglio; Claude Leclerc
Journal:  Blood       Date:  2008-08-12       Impact factor: 22.113

6.  The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells.

Authors:  Emer Bourke; Daniela Bosisio; Josee Golay; Nadia Polentarutti; Alberto Mantovani
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

7.  Resting B lymphocytes as APC for naive T lymphocytes: dependence on CD40 ligand/CD40.

Authors:  D E Evans; M W Munks; J M Purkerson; D C Parker
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

8.  Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells.

Authors:  Antje Heit; Tobias Maurer; Hubertus Hochrein; Stefan Bauer; Katharina M Huster; Dirk H Busch; Hermann Wagner
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

9.  Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12.

Authors:  A Krug; A Towarowski; S Britsch; S Rothenfusser; V Hornung; R Bals; T Giese; H Engelmann; S Endres; A M Krieg; G Hartmann
Journal:  Eur J Immunol       Date:  2001-10       Impact factor: 5.532

10.  Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.

Authors:  Veit Hornung; Simon Rothenfusser; Stefanie Britsch; Anne Krug; Bernd Jahrsdörfer; Thomas Giese; Stefan Endres; Gunther Hartmann
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

View more
  14 in total

1.  A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells.

Authors:  Melissa Santone; Susanna Aprea; Tom Y H Wu; Michael P Cooke; M Lamine Mbow; Nicholas M Valiante; James S Rush; Stephanie Dougan; Ana Avalos; Hidde Ploegh; Ennio De Gregorio; Cecilia Buonsanti; Ugo D'Oro
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Lymphocryptovirus Infection of Nonhuman Primate B Cells Converts Destructive into Productive Processing of the Pathogenic CD8 T Cell Epitope in Myelin Oligodendrocyte Glycoprotein.

Authors:  S Anwar Jagessar; Inge R Holtman; Sam Hofman; Elena Morandi; Nicole Heijmans; Jon D Laman; Bruno Gran; Bart W Faber; Sander I van Kasteren; Bart J L Eggen; Bert A 't Hart
Journal:  J Immunol       Date:  2016-07-13       Impact factor: 5.422

3.  B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma.

Authors:  Marianela Candolfi; James F Curtin; Kader Yagiz; Hikmat Assi; Mia K Wibowo; Gabrielle E Alzadeh; David Foulad; A K M G Muhammad; Sofia Salehi; Naomi Keech; Mariana Puntel; Chunyan Liu; Nicholas R Sanderson; Kurt M Kroeger; Robert Dunn; Gislaine Martins; Pedro R Lowenstein; Maria G Castro
Journal:  Neoplasia       Date:  2011-10       Impact factor: 5.715

4.  Staphylococcus aureus peptidoglycan (PGN) induces pathogenic autoantibody production via autoreactive B cell receptor clonal selection, implications in systemic lupus erythematosus.

Authors:  Wangbin Ning; Da Cheng; Philip H Howe; Chuanxiu Bian; Diane L Kamen; Zhenwu Luo; Xiaoyu Fu; Elizabeth Ogunrinde; Liuqing Yang; Xu Wang; Quan-Zhen Li; Jim Oates; Weiru Zhang; David White; Zhuang Wan; Gary S Gilkeson; Wei Jiang
Journal:  J Autoimmun       Date:  2022-07-08       Impact factor: 14.511

5.  Tumor infiltrating CD19+ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.

Authors:  Zhiyuan Lin; Li Liu; Yu Xia; Xiang Chen; Ying Xiong; Yang Qu; Jiajun Wang; Qi Bai; Jianming Guo; Jiejie Xu
Journal:  Oncoimmunology       Date:  2018-08-06       Impact factor: 8.110

6.  The different clinical effects of anti-BLyS, anti-APRIL and anti-CD20 antibodies point at a critical pathogenic role of γ-herpesvirus infected B cells in the marmoset EAE model.

Authors:  S Anwar Jagessar; Zahra Fagrouch; Nicole Heijmans; Jan Bauer; Jon D Laman; Luke Oh; Thi Migone; Ernst J Verschoor; Bert A 't Hart
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-19       Impact factor: 4.147

Review 7.  The role of B cells and humoral immunity in Mycobacterium tuberculosis infection.

Authors:  Lee Kozakiewicz; Jiayao Phuah; Joanne Flynn; John Chan
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

8.  Microfluidic squeezing for intracellular antigen loading in polyclonal B-cells as cellular vaccines.

Authors:  Gregory Lee Szeto; Debra Van Egeren; Hermoon Worku; Armon Sharei; Brian Alejandro; Clara Park; Kirubel Frew; Mavis Brefo; Shirley Mao; Megan Heimann; Robert Langer; Klavs Jensen; Darrell J Irvine
Journal:  Sci Rep       Date:  2015-05-22       Impact factor: 4.379

9.  The Primate EAE Model Points at EBV-Infected B Cells as a Preferential Therapy Target in Multiple Sclerosis.

Authors:  Bert A 't Hart; S Anwar Jagessar; Krista Haanstra; Ernst Verschoor; Jon D Laman; Yolanda S Kap
Journal:  Front Immunol       Date:  2013-06-13       Impact factor: 7.561

10.  A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanisms.

Authors:  Ying-Chyi Song; Shih-Jen Liu
Journal:  Sci Rep       Date:  2015-07-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.